TY - JOUR
T1 - Effects of antenatal corticosteroids on neonatal outcomes in very-low-birth-weight preterm newborns
T2 - A 10-year retrospective study in a medical center
AU - Wang, Ya Chen
AU - Tseng, Hsing I.
AU - Yang, San Nan
AU - Lu, Chu Chong
AU - Wu, Jiunn Ren
AU - Dai, Zen Kong
AU - Hsu, Jong Hau
AU - Chen, Hsiu Lin
PY - 2012/6
Y1 - 2012/6
N2 - Objective: To evaluate the effects on neonatal outcomes between very-low-birth-weight (VLBW) preterm newborns with and without maternal use of antenatal corticosteroids (ACS). Methods: We retrospectively reviewed medical records of VLBW premature infants who were admitted to Kaohsiung Medical University Hospital between 1999 and 2008. A total of 256 infants were enrolled in this study. A total of 174 neonates did not receive any ACS, and 82 neonates received ACS. A total of 37 neonates received one dose of ACS, and 45 neonates received more than one dose of ACS, referred to as "multiple-dose ACS." In addition, these 82 infants were divided to betamethasone group (n = 8) and dexamethasone group (n = 50) with 24 infants excluded because of inadequate information. Results: Neonates with multiple-dose ACS had lower incidence of surfactant use and lower rate of intubation than neonates without ACS. There were no differences in the occurrences of intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, sepsis, and chronic lung disease with one-dose vs. multiple-dose ACS and in the betamethasone group vs. the dexamethasone group. Conclusions: ACS reduces the need for exogenous surfactant, and the need for endotracheal tube insertion at birth in VLBW premature infants.
AB - Objective: To evaluate the effects on neonatal outcomes between very-low-birth-weight (VLBW) preterm newborns with and without maternal use of antenatal corticosteroids (ACS). Methods: We retrospectively reviewed medical records of VLBW premature infants who were admitted to Kaohsiung Medical University Hospital between 1999 and 2008. A total of 256 infants were enrolled in this study. A total of 174 neonates did not receive any ACS, and 82 neonates received ACS. A total of 37 neonates received one dose of ACS, and 45 neonates received more than one dose of ACS, referred to as "multiple-dose ACS." In addition, these 82 infants were divided to betamethasone group (n = 8) and dexamethasone group (n = 50) with 24 infants excluded because of inadequate information. Results: Neonates with multiple-dose ACS had lower incidence of surfactant use and lower rate of intubation than neonates without ACS. There were no differences in the occurrences of intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, sepsis, and chronic lung disease with one-dose vs. multiple-dose ACS and in the betamethasone group vs. the dexamethasone group. Conclusions: ACS reduces the need for exogenous surfactant, and the need for endotracheal tube insertion at birth in VLBW premature infants.
KW - antenatal corticosteroids
KW - patent ductus arteriosus
KW - prematurity
KW - respiratory distress syndrome
KW - very low birth weight
UR - https://www.scopus.com/pages/publications/84863615087
U2 - 10.1016/j.pedneo.2012.04.004
DO - 10.1016/j.pedneo.2012.04.004
M3 - 文章
C2 - 22770106
AN - SCOPUS:84863615087
SN - 1875-9572
VL - 53
SP - 178
EP - 183
JO - Pediatrics and Neonatology
JF - Pediatrics and Neonatology
IS - 3
ER -
